Connect with us

Technology

UBC AND THREAD EXPAND SITEPLUS OFFERING AND ACTIVE STUDIES WITH BIOPHARMA SPONSORS TO OPTIMIZE EVIDENCE GENERATION

Published

on

Collaboration augments full-featured central site model with additional research services and technology to widen recruitment access and improve the site and patient experience

KING OF PRUSSIA, Pa. and CARY, N.C., June 25, 2024 /PRNewswire/ — United BioSource LLC (UBC), a leading provider of evidence development solutions, and Thread®, a leading decentralized research, electronic clinical outcome assessment (eCOA) and consulting services provider, today announced the expansion of their SitePlus solution. This joint offering, the outcome of a successful six-year working relationship, has provided early recruitment and retention success for biopharma customers since its March 2023 launch. UBC and Thread have now expanded the solution to offer additional central site services and technology features for both post-approval research and Phase II/III interventional clinical trials.

SitePlus provides a next-generation research model that can be initiated from initial study design and launch or added alongside any ongoing Phase II-IV study nationwide. SitePlus offers a central site model which extends the reach of sites and widens the addressable patient population. The solution leverages a centralized technology platform to accelerate patient recruitment, facilitate home health engagement, securely capture data, and enable superior patient retention.

SitePlus combines UBC’s industry leading late-stage research solutions with Thread’s technology to empower central site study designs focused on patients while improving the research experience for all participating sites. It further enables biopharma sponsors to contract with UBC as a central research center inclusive of investigator and study coordinating center concierge support services. SitePlus connects UBC’s central principal investigator, home health, and patient coordinating center expertise with Thread’s unified technology platform and consulting services for data capture, virtual visits, and optimized patient engagement.

“Study designs that rely exclusively on brick-and-mortar site models can benefit from the enhancements SitePlus offers to help meet their patient enrollment and retention goals,” said Bekki Bracken Brown, President & Chief Executive Officer, UBC. “Studies leveraging a hybrid approach have seen success in reaching a more representative patient population, faster, and maintaining patient engagement. The Thread technology platform supports our central site offering by enabling a more flexible approach to patient recruitment and engagement and strengthens the return on evidence generation for our customers. “

UBC and Thread’s enterprise collaboration continues to enrich UBC’s modernized study designs and eCOA solutions that enable patient-centered research studies to be conducted in the clinic, in the home, and on-the-go.

“Based on strong early results with SitePlus for our joint customers, we are excited to expand its features to offer solutions in both interventional and post-approval research studies,” said Thread Co-Founder and CEO John Reites. “We appreciate UBC’s continued partnership and the feedback from our biopharma customers to add more value to this important innovative offering’s market growth.”

Learn more about SitePlus at www.AddSitePlus.com

About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit www.ubc.com.

About Thread
Thread’s® purpose is to leverage its decentralized research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, Thread empowers studies to be accessible, efficient, and centered on the patient. Backed by health care investors Water Street Healthcare Partners and JLL Partners, Thread is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021/2022 and positioned in the Leader’s Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment 2022. Visit Threadresearch.com to learn more. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ubc-and-thread-expand-siteplus-offering-and-active-studies-with-biopharma-sponsors-to-optimize-evidence-generation-302173322.html

SOURCE UBC; Thread

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Agri-Food Tech Startups Led by Taiwan’s HAOSHi Attend SusHi Tech Tokyo 2026 to Build Industry and Investment Connections

Published

on

By

TAIPEI and TOKYO, April 28, 2026 /PRNewswire/ — A delegation of three food-tech startups led by Taiwan-based agri-food tech accelerator HAOSHi recently participated in SusHi Tech Tokyo 2026, a global innovation event held in Japan. Through the exhibition and local industry engagement, the initiative aims to help Taiwanese startups establish partnerships with Japanese companies and explore potential investment opportunities.

SusHi Tech Tokyo has emerged as a key innovation platform in Japan, with a focus on urban development and technology applications. As Japan transitions into a super-aged society, demand for functional foods and precision health solutions continues to rise. In response, the Taiwanese delegation brought a focused approach to health and biotech applications, showcasing the R&D capabilities of Taiwan’s food-tech and precision nutrition sectors.

Ahead of the exhibition, HAOSHi worked with Sustainable Food Asia (SFA), a Japan-based organization engaged in sustainable food innovation, to arrange industry exchanges and company visits, giving the startups a more practical understanding of the local market. The trip also facilitated discussions between the Taiwanese teams and Japanese startups including Algalex, Eclipse Foods, and Morus, covering supply chain collaboration and market entry strategies. Through product demonstrations and tastings, the startups established initial business connections with companies in the cosmeceuticals, biotech, food manufacturing, and supply chain sectors.

The two organizations also co-hosted “Sustainable Food Night,” a networking event that drew around 30 representatives from established companies, startups, and investors. Discussions centered on collaboration opportunities in the agri-food tech sector across Taiwan, Japan, and Southeast Asia, with the broader aim of strengthening regional connectivity.

The three participating startups were Space Ark Bio, King Noodles, and Leeuwenhoek Laboratories, which specialize in fermentation applications, functional foods, and precision nutrition, respectively. Amber Lin, CEO of HAOSHi, said that the exhibition and in-market networking helped lay the groundwork for the startups to enter the market and support follow-up business discussions. The initiative also aligns with the goal of Startup Island Taiwan (SIT), which aims to connect Taiwanese startups more closely with the global innovation ecosystem.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/agri-food-tech-startups-led-by-taiwans-haoshi-attend-sushi-tech-tokyo-2026-to-build-industry-and-investment-connections-302756448.html

SOURCE HAOSHi Accelerator

Continue Reading

Technology

DB HiTek to Participate in PCIM 2026, Strengthening Its Presence in the European Market

Published

on

By

Europe’s largest power semiconductor exhibition to be held in Nuremberg, Germany, from June 9 to 11Showcasing latest developments in SiC and GaN, highlighting its power semiconductor capabilities

SEOUL, South Korea, April 29, 2026 /PRNewswire/ — DB HiTek, a leading 8-inch pure-play foundry, announced its participation in PCIM (Power Conversion and Intelligent Motion) Europe 2026, the continent’s premier exhibition for power semiconductors. The event will take place in Nuremberg, Germany, from June 9 to 11 (local time), as the company continues expanding its presence in the European market.

Following its successful debut at PCIM in 2025—where the company held face-to-face meetings with dozens of customers to discuss process technologies and collaboration opportunities—DB HiTek is building on that momentum. With over 1,000 booth visitors last year and ongoing business discussions, the company expects these engagements to translate into tangible business results this year through continued partnerships.

At this year’s event, DB HiTek will present progress in its next-generation SiC (Silicon Carbide) and GaN (Gallium Nitride) processes. The company will also highlight its industry-leading BCDMOS (Bipolar-CMOS-DMOS) technology, a core strength of its power management portfolio. A robust schedule of meetings with global clients is already in place, reflecting continued growth in collaboration.

According to market research firm Yole Développement, the global SiC and GaN power semiconductor markets are set for rapid growth. The SiC market is projected to grow from approximately $4.8 billion in 2026 to $10.4 billion by 2030, representing a compound annual growth rate (CAGR) of 21%. Over the same period, the GaN market is expected to expand from $900 million to $2.9 billion, reflecting a CAGR of 33%.

DB HiTek started MPW (Multi-Project Wafer) runs for its SiC and GaN processes in December 2025, producing samples for more than 10 customer products. These were delivered between March and April 2026. Customer evaluations are underway, with feedback to be incorporated into final process verification. Full-scale mass production is scheduled to begin in 2027.

Currently, DB HiTek maintains mass production relationships with approximately 400 customers, primarily focused on its flagship power semiconductor products. The company also works with a broad client base using specialized image sensor technologies, including X-ray, Global Shutter, and SPAD (Single Photon Avalanche Diode). Its application mix is increasingly shifting toward industrial and automotive-grade products, reflecting growing demand from these sectors.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/db-hitek-to-participate-in-pcim-2026-strengthening-its-presence-in-the-european-market-302754538.html

SOURCE DB HiTek

Continue Reading

Technology

LG Display’s 27-inch DFR Gaming OLED panel wins SID’s ‘Display of the Year’

Published

on

By

SEOUL, South Korea, April 28, 2026 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced that its 27-inch 540/720Hz Dynamic Frequency & Resolution (DFR) Gaming OLED panel has been awarded “Display of the Year” by the Society for Information Display (SID), receiving high acclaim for redefining the gaming display paradigm and accelerating market differentiation.

The “Display of the Year” award is SID’s most prestigious distinction, presented to the most groundbreaking display product launched during the previous year that is expected to lead the future of the industry.

This achievement recognizes LG Display’s new user-centered display paradigm. The product’s standout feature is the company’s proprietary DFR technology, which allows users to freely select the mode that suits their preferred gaming style.

High-refresh-rate mode particularly proves its value in game genres where rapid screen transitions are essential and victory is decided in a split second — like first-person shooters or racing games. By supporting an industry-leading refresh rate of 720Hz with HD resolution, this mode eliminates ghosting and motion blur even in the fastest scenes, enabling overwhelming gaming performance.

High-resolution mode provides an optimized visual experience for games based on stunning graphics. It simultaneously delivers QHD resolution and a 540Hz refresh rate. To overcome the conventional limitation where picture quality drops once the refresh rate exceeds 500Hz, LG Display applied a proprietary algorithm, securing the two core elements of a high refresh rate and high picture quality.

As a result, the panel obtained ClearMR 21000 certification, the highest rating from the Video Electronics Standards Association (VESA).

“Our goal is to continue leading the gaming display market by leveraging LG Display’s differentiated OLED technologies and relentless pursuit of innovation,” said Young-seok Choi, Chief Technology Officer of LG Display.

SID is the world’s largest display society with more than 7,000 industry experts, researchers, and professors. It hosts Display Week annually, featuring new technologies, product exhibitions, and academic presentations. SID Display Week 2026 will take place in Los Angeles, California from May 3 to 8.

※ LG Display 27-inch 540/720Hz (DFR) OLED Gaming Monitor Panel Specifications

Category

High-refresh-rate mode

High-resolution mode

Peak Brightness

1,500nits

1,500nits

Refresh Rate / Resolution

720Hz / HD

540Hz / QHD

Response Time

0.02ms

0.02ms

 

About LG Display
LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Team Leader, Communication Team
Email: hjy05@lgdisplay.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lg-displays-27-inch-dfr-gaming-oled-panel-wins-sids-display-of-the-year-302755502.html

SOURCE LG Display

Continue Reading

Trending